Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population

References

• Kantarci O, Wingerchuk D. Epidemiology and natural history of multiple sclerosis: new insights. Curr Opin Neurol 2006;19: 248–54
   PubMed Web of Science ®Google Scholar
• Flachenecker P, Zettl UK, Gotze U, et al. [MS registry in Germany – design and first results of the pilot phase]. Nervenarzt 2005;76:967–75
   PubMedGoogle Scholar
• Goodkin DE. The natural history of multiple sclerosis. In: Rudick RA, Goodkin DE, eds. Treatment of Multiple Sclerosis: Trial Design, Results and Future Perspectives. New York: Springer-Verlag, 1992:17–46
   Google Scholar
• Minden SL, Orav J, Reich P. Depression in multiple sclerosis. Gen Hosp Psychiatry 1987;9:426–34
   PubMed Web of Science ®Google Scholar
• Lechtenberg R. Multiple sclerosis fact book. Philadelphia: F.A. Davis, 1988
   Google Scholar
• Rao SM, Leo GJ, Ellington L, et al. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology 1991;41:692–6
   Google Scholar
• Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991;41:685–91
   Google Scholar
• Maurelli M, Marchioni E, Cerretano R, et al. Neuropsychological assessment in MS: clinical, neurophysiological and neuroradiological relationships. Acta Neurol Scand 1992;86:124–8
   PubMed Web of Science ®Google Scholar
• Joffe RT, Lippert GP, Gray TA, et al. Mood disorder and multiple sclerosis. Arch Neurol 1987;44:376–8
   PubMed Web of Science ®Google Scholar
• Schwartz CE, Fierston S. The two sides of pseudobulbar disorder in multiple sclerosis: comparing one patient’s experience with a review of the neurologic literature. Neurorehabilitation 1995;5:359–65
   PubMed Web of Science ®Google Scholar
• Murphy N, Confavreux C, Haas J, et al. Quality of life in multiple sclerosis in France, Germany, and the United Kingdom. Cost of Multiple Sclerosis Study Group. J Neurol Neurosurg Psychiatry 1998;65:460–6
   PubMed Web of Science ®Google Scholar
• Rothwell PM, McDowell Z, Wong CK, Dorman PJ. Doctors and patients don’t agree: cross sectional study of patients’ and doctors’ perceptions and assessments of disability in multiple sclerosis. BMJ 1997;314:1580–3
   PubMed Web of Science ®Google Scholar
• Rothwell PM. Quality of life in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;65:433
   PubMed Web of Science ®Google Scholar
• Nortvedt MW, Riise T, Myhr KM, Nyland HI. Quality of life in multiple sclerosis: measuring the disease effects more broadly. Neurology 1999;53:1098–103
   PubMed Web of Science ®Google Scholar
• Rudick RA, Miller D, Clough JD, et al. Quality of life in multiple sclerosis. Comparison with inflammatory bowel disease and rheumatoid arthritis. Arch Neurol 1992;49:1237–42
   Google Scholar
• Compston A, Coles A. Multiple sclerosis. Lancet 2002;359: 1221–31
   PubMed Web of Science ®Google Scholar
• Randomized controlled trial of interferon- beta-1a in secondary progressive MS: clinical results. Neurology 2001;56:1496–504
   PubMed Web of Science ®Google Scholar
• Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1995;45:1277–85
   Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285–94
   Google Scholar
• PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498–504
   Google Scholar
• European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491–7
   Google Scholar
• Rio J, Porcel J, Tellez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005;11:306–9
   PubMed Web of Science ®Google Scholar
• Clanet M. Motivating MS patients: the Annual Convention 2005 of the MS Forum, 22 May 2005, St Julians, Malta. Int MS J 2005;12:109
   PubMedGoogle Scholar
• Fuchs R, Seelig H, Kilian D. Self-concordance and sport participation: a cluster analytical differentiation of varying forms of maintainers and drop-outs. Z Gesundheitspsychol 2006;13:126–38
   Google Scholar
• Kobelt G. Costs and quality of life for patients with multiple sclerosis in Belgium. Eur J Health Econ 2006;7 Suppl 2:24–33
   PubMedGoogle Scholar
• Kobelt G, Berg J, Lindgren P. Costs and quality of life in multiple sclerosis in The Netherlands. Eur J Health Econ 2006;7 Suppl 2:55–64
   PubMedGoogle Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in the United Kingdom. Eur J Health Econ 2006;7 Suppl 2:96–104
   PubMedGoogle Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Germany. Eur J Health Econ 2006;7 Suppl 2:34–44
   PubMedGoogle Scholar
• Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 2006;66:1696–702
   PubMed Web of Science ®Google Scholar
• Shinto L, Yadav V, Morris C, et al. The perceived benefit and satisfaction from conventional and complementary and alternative medicine (CAM) in people with multiple sclerosis. Complement Ther Med 2005;13:264–72
   PubMed Web of Science ®Google Scholar
• Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. Patient and community preferences for treatments and health states in multiple sclerosis. Mult Scler 2003;9:311–19
   Google Scholar
• Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003;61:551–4
   PubMed Web of Science ®Google Scholar
• O’Rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005;11:46–50
   Google Scholar
• Goodin DS, Frohman EM, Garmany GP, Jr., et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58:169–78
   PubMed Web of Science ®Google Scholar
• Neilley LK, Goodin DS, Goodkin DE, Hauser SL. Side effect profile of interferon beta-1b in MS: results of an open label trial. Neurology 1996;46:552–4
   PubMed Web of Science ®Google Scholar
• Guarnaccia JB, Aslan M, O’Connor TZ, et al. Quality of life for veterans with multiple sclerosis on disease-modifying agents: relationship to disability. J Rehabil Res Dev 2006;43: 35–44
   Google Scholar
• Hayes RP, Bowman L, Monahan PO, et al. Understanding diabetes medications from the perspective of patients with type 2 diabetes: prerequisite to medication concordance. Diabetes Educ 2006;32:404–14
   PubMed Web of Science ®Google Scholar
• Langer-Gould A, Moses HH, Murray TJ. Strategies for managing the side effects of treatments for multiple sclerosis. Neurology 2004;63 Suppl 5: S35–S41
   Google Scholar
• Mohr DC, Goodkin DE, Likosky W, et al. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 1997;54:531–3
   PubMed Web of Science ®Google Scholar
• PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498–504
   Google Scholar
• Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 2002;59:1496–506
   PubMed Web of Science ®Google Scholar
• The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655–61
   Google Scholar
• Fraser C, Morgante L, Hadjimichael O, Vollmer T. A prospective study of adherence to glatiramer acetate in individuals with multiple sclerosis. J Neurosci Nurs 2004;36:120–9
   PubMedGoogle Scholar
• Fraser C, Hadjimichael O, Vollmer T. Predictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosis. J Neurosci Nurs 2003;35:163–70
   Google Scholar
• Fraser C, Hadjimichael O, Vollmer T. Predictors of adherence to Copaxone therapy in individuals with relapsing-remitting multiple sclerosis. J Neurosci Nurs 2001;33:231–9
   Google Scholar
• Mohr DC, Boudewyn AC, Likosky W, et al. Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Ann Behav Med 2001;23: 125–32
   PubMed Web of Science ®Google Scholar
• Mohr DC, Goodkin DE, Likosky W, et al. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment. Mult Scler 1996;2:222–6
   PubMedGoogle Scholar